Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M111,261Revenue $M42,750Net Margin (%)17.6Z-Score2.2
Enterprise Value $M136,172EPS $3.6Operating Margin %22.5F-Score6
P/E(ttm))17.3Cash Flow Per Share $0Pre-tax Margin (%)21.0Higher ROA y-yY
Price/Book14.110-y EBITDA Growth Rate %3.1Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.05-y EBITDA Growth Rate %2.5Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-22.6ROA % (ttm)10.4Higher Current Ratio y-yN
Dividend Yield %5.7Insider Buy (3m)0ROE % (ttm)68.0Less Shares Outstanding y-yY
Payout Ratio %93.0Shares Outstanding M2,402ROI % (ttm)14.0Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKHOTCHKIS & WILEY 2014-09-30 Add0.98%$46.29 - $54.52
($49.01)
$ 46.4-5%Add 118.31%10,804,564
GSKCharles Brandes 2014-09-30 Add0.56%$46.29 - $54.52
($49.01)
$ 46.4-5%Add 36.63%3,415,717
GSKIrving Kahn 2014-09-30 Buy 0.38%$46.29 - $54.52
($49.01)
$ 46.4-5%New holding, 51000 sh.51,000
GSKNWQ Managers 2014-09-30 Add0.03%$46.29 - $54.52
($49.01)
$ 46.4-5%Add 39.82%208,125
GSKDavid Dreman 2014-09-30 Buy 0.01%$46.29 - $54.52
($49.01)
$ 46.4-5%New holding, 1328 sh.1,328
GSKDodge & Cox 2014-09-30 Reduce-1.11%$46.29 - $54.52
($49.01)
$ 46.4-5%Reduce -35.93%38,589,161
GSKHOTCHKIS & WILEY 2014-06-30 Add0.93%$51.55 - $56.39
($54.16)
$ 46.4-14%Add 13358.6%4,949,118
GSKCharles Brandes 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 46.4-14%Add 15.52%2,500,048
GSKJohn Rogers 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 46.4-14%Add 49.33%988,772
GSKJames Barrow 2014-06-30 Buy 0.02%$51.55 - $56.39
($54.16)
$ 46.4-14%New holding, 270900 sh.270,900
GSKPRIMECAP Management 2014-06-30 Reduce-0.25%$51.55 - $56.39
($54.16)
$ 46.4-14%Reduce -43.82%5,156,449
GSKJohn Rogers 2014-03-31 Add0.16%$50.9 - $56.66
($54.07)
$ 46.4-14%Add 57.21%662,150
GSKHOTCHKIS & WILEY 2014-03-31 Buy 0.01%$50.9 - $56.66
($54.07)
$ 46.4-14%New holding, 36773 sh.36,773
GSKJohn Hussman 2014-03-31 Reduce-0.38%$50.9 - $56.66
($54)
$ 46.4-14%Reduce -23.61%323,500
GSKVanguard Health Care Fund 2014-03-31 Sold Out -0.11%$50.9 - $56.66
($54)
$ 46.4-14%Sold Out0
GSKNWQ Managers 2014-03-31 Reduce-0.03%$50.9 - $56.66
($54.07)
$ 46.4-14%Reduce -28.91%148,800
GSKJohn Hussman 2013-12-31 Add1.51%$49.31 - $53.68
($51.87)
$ 46.4-10%Add 1702.13%423,500
GSKJohn Rogers 2013-12-31 Add0.19%$49.31 - $53.68
($51.87)
$ 46.4-10%Add 208.93%421,201
GSKCharles Brandes 2013-12-31 Add0.16%$49.31 - $53.68
($51.87)
$ 46.4-10%Add 13.11%2,145,461
GSKJoel Greenblatt 2013-12-31 Buy 0.11%$49.31 - $53.68
($51.87)
$ 46.4-10%New holding, 83452 sh.83,452
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GSK Irving Kahn 2014-09-3051,00000.38New Buy
GSK David Dreman 2014-09-301,32800.01New Buy
GSK HOTCHKIS & WILEY 2014-09-3010,804,5640.451.8+118.31%
GSK NWQ Managers 2014-09-30208,1250.010.11+39.82%
GSK Charles Brandes 2014-09-303,415,7170.142.1+36.63%
GSK John Rogers 2014-09-301,005,6340.040.6+1.71%
GSK Ken Fisher 2014-09-3011,488,5940.481.1+1.08%
GSK James Barrow 2014-09-30270,9000.010.02
GSK John Hussman 2014-09-30323,5000.011.3
GSK Jean-Marie Eveillard 2014-09-30100
GSK Joel Greenblatt 2014-09-3083,46200.04-0.08%
GSK Tweedy Browne 2014-09-30140,2780.010.15-1.29%
GSK PRIMECAP Management 2014-09-304,874,6350.20.24-5.47%
GSK Dodge & Cox 2014-09-3038,589,1611.611.7-35.93%
Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29776.18view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12286.25view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14231.07view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12286.25view

Press Releases about GSK :

    Quarterly/Annual Reports about GSK:

      News about GSK:

      Articles On GuruFocus.com
      Jeff Auxier Buys Berkshire Hathaway in Third Quarter Nov 18 2014 
      Irving Kahn Starts New Position In GlaxoSmithKline Nov 13 2014 
      Irving Kahn Buys Stake in GlaxoSmithKline During Q3 2014 Nov 12 2014 
      Kahn Brothers' Third Quarter Numbers Nov 07 2014 
      Tweedy Browne Global Value Fund's Top Picks for Q3 Oct 21 2014 
      Diamond Hill Capital Comments on GlaxoSmithKline PLC Oct 17 2014 
      Dodge & Cox’ Stock Fund Third Quarter 2014 Commentary Oct 16 2014 
      Ebola: Is The Cure Out There? Oct 14 2014 
      Guru Stocks at 52-Week Lows: GE, BHP, TOT, BP, GSK Oct 12 2014 
      Guru Stocks at 52-Week Lows: BHP, GSK, UTX, SAP, TEF Sep 30 2014 


      More From Other Websites
      Buying Glaxo's Biotech Stock Throwbacks Proves Profitable Nov 24 2014
      BioMarin Buying Prosensa, Backing Up Troubled Drug Nov 24 2014
      GSK shareholders to vote on Novartis deal on Dec. 18 Nov 24 2014
      Publication of Circular and Notice of General Meeting relating to the proposed major transaction... Nov 24 2014
      Is GlaxoSmithKline plc’s Dividend Safe? Nov 21 2014
      Will GlaxoSmithKline plc Be Back To Growth By 2016? Nov 20 2014
      GlaxoSmithKline plc Is Best In Class When It Comes To Affordable Medicine Nov 19 2014
      The Top Performing And Yielding Dividend Funds Nov 18 2014
      Good News From A Failed Digital Health Randomized Clinical Trial: It Was Performed Nov 18 2014
      Director/PDMR Shareholding Nov 18 2014
      Director/PDMR Shareholding Nov 14 2014
      Director/PDMR Shareholding- Amendment Nov 14 2014
      Why GlaxoSmithKline plc And HSBC Holdings plc Can Be The FTSE 100′s Stars Of 2015! Nov 14 2014
      Europe shares open higher with positive GDP figures Nov 14 2014
      Is A Boston University Professor's Plan For Lower Drug Costs Viable? Nov 13 2014
      GlaxoSmithKline plc Is Working Hard To Unlock Value For Investors Nov 13 2014
      Ebola To Have A Global Burden Of $5.9 Billion By End Of 2016 Nov 12 2014
      Blocklisting Interim Review Nov 12 2014
      Insys Q3 Beats Estimates, Helping Stock Rebound Nov 11 2014
      The Inaccurate And Unfair WHO Attack On Pharma Ebola Efforts Nov 10 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK